Latest On RaySearch Laboratories AB (publ) (RSLBF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-17 13:00 EST | News | RaySearch Laboratories GAAP EPS of SEK0.51, revenue of SEK230.2M | N/A |  |
| 2023-02-28 15:12 EST | News | RaySearch Laboratories GAAP EPS of SEK0.41, revenue of SEK264.4M | N/A | |
| 2022-08-29 07:42 EST | News | RaySearch Laboratories GAAP EPS of -SEK 0.58, revenue of SEK 160.2M | N/A | |
| 2022-05-18 20:04 EST | News | RaySearch Laboratories GAAP EPS of SEK 0.56, revenue of SEK 208.1M | N/A | |
| 2021-02-25 00:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 19:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-21 18:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-28 15:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 03:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 19:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:23 EST | Financials | Company financials have been released. | Neutral | |
About RaySearch Laboratories AB (publ) (RSLBF):
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomo therapy, and electron beam radiation therapy; and RayCare, an oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, RayCare flow, and data handling and machine learning. In addition, it offers RayCommand, a treatment control system that is compatible with multiple hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system, which turns patient data into insights. Further, the company provides training courses, as well as customer support services. RaySearch Laboratories AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
General
- Name RaySearch Laboratories AB (publ)
- Symbol RSLBF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryHealth Information Services
- Full Time Employees 405
- Fiscal Year EndDecember
- Web URLhttp://www.raysearchlabs.com
Valuation
- Trailing PE 137.04
- Forward PE 32.47
- Price/Sales (Trailing 12 Mt.) 4.38
- Price/Book (Most Recent Quarter) 4.49
- Enterprise Value Revenue 0.5
- Enterprise Value EBITDA 10.4
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -1%
- Return on Equity -1%
- Revenue Per Share $0
- Gross Profit 608.24 million
- Quarterly Earnings Growth -31.8%
Highlights
- Market Capitalization 365.33 million
Share Statistics
- Shares Outstanding 25.83 million
- Shares Float 24.97 million
- % Held by Insiders 755%
- % Held by Institutions 63.08%
Technicals
- Beta 1.15
- 52 Week High $11.17
- 52 Week Low $5.05
- 50 Day Moving Average 10.71
- 200 Day Moving Average 10.89
Dividends
- Dividend Date N/A
- ExDividend Date 2016-05-18
- Dividend Yield 0%
RaySearch Laboratories AB (publ) (RSLBF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
RaySearch Laboratories AB (publ) (RSLBF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | -$0.05 | -$0.13 | 61.38% |
| 2020-06-30 | 2020-09-30 | $163.76 million | -$0.09 | -$0.39 | 78.13% |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.03 | $0.61 | -104.72% |
| 2019-12-31 | 2020-03-31 | $234.5 million | $0.12 | $0.96 | -87.57% |
| 2019-09-30 | 2019-12-31 | $144.35 million | $0.06 | -$0.20 | 129.45% |
| 2019-06-30 | 2019-09-30 | $189.66 million | -$0.02 | $0.57 | -103.93% |
| 2019-03-31 | 2019-06-30 | $173.08 million | $0.07 | $0.86 | -92.02% |
| 2018-12-31 | 2019-03-31 | $219.44 million | $0.05 | $0.85 | -93.67% |
| 2018-09-30 | 2018-12-31 | $150.48 million | $0.11 | $0.28 | -61.64% |
| 2018-06-30 | 2018-09-30 | $141.04 million | $0.04 | $0.58 | -92.43% |
| 2018-03-31 | 2018-06-30 | $35.11 million | $0.07 | $0.75 | -91.07% |
| 2017-12-31 | 2018-03-31 | $246.14 million | $0.04 | $1.60 | -97.46% |
| 2017-09-30 | 2017-12-31 | $131.06 million | $0.26 | $0.02 | 1184.5% |
| 2017-06-30 | 2017-09-30 | $141.63 million | $-0.00 | $0.72 | -100.51% |
| 2017-03-31 | 2017-06-30 | $126.79 million | $0.07 | $0.80 | -91.3% |
| 2016-12-31 | 2017-03-31 | $191.36 million | $0.09 | $1.96 | -95.64% |
| 2016-09-30 | 2016-12-31 | $0.24 | $0.80 | -69.61% | |
| 2016-06-30 | 2016-09-30 | $0.10 | $0.56 | -82.52% | |
| 2016-03-31 | 2016-06-30 | $0.10 | $0.54 | -81.65% | |
| 2015-12-31 | 2016-03-31 | $0.06 | $1.48 | -95.68% | |
| 2015-09-30 | 2015-12-31 | $0.11 | $0.59 | -80.53% | |
| 2015-06-30 | 2015-09-30 | $0.05 | $0.07 | -28.43% | |
| 2015-03-31 | 2015-06-30 | -$0.01 | $0.20 | -104.8% | |
| 2014-12-31 | 2015-03-31 | $0.08 | $0.83 | -89.81% | |
| 2014-09-30 | 2014-12-31 | $0.15 | $0.03 | 407% | |
| 2014-06-30 | 2014-09-30 | $0.05 | -$0.02 | 370% | |
| 2014-03-31 | 2014-06-30 | $0.00 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.03 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.02 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.07 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.07 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.02 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.11 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.01 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.04 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.02 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.03 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.04 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $-0.00 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.01 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.05 | $0.00 |
RaySearch Laboratories AB (publ) (RSLBF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 44.93 million | N/A | 46.89 million |
| Income Before Tax | N/A | N/A | -13 million | N/A | 20.61 million |
| Selling General Administrative | N/A | N/A | 90.93 million | N/A | 124.37 million |
| Gross Profit | N/A | N/A | 152.29 million | N/A | 208.64 million |
| Ebit | N/A | N/A | -10.95 million | N/A | 37.38 million |
| Operating Income | N/A | N/A | -10.95 million | N/A | 37.38 million |
| Income Tax Expense | 121000 | -4.47 million | -3.81 million | 10.76 million | 1.68 million |
| Total Revenue | N/A | N/A | 163.76 million | N/A | 234.5 million |
| Cost of Revenue | N/A | N/A | 11.47 million | N/A | 25.86 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -16.76 million |
| Net Income From Continuing Operations | N/A | N/A | -9.2 million | N/A | 18.94 million |
| Net Income Applicable to Common Shares | -14.16 million | -26.18 million | -9.2 million | 40.46 million | 18.94 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -55.91 million | N/A | N/A | -48.57 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -45.37 million | -55.91 million | -60.21 million | -60.99 million | -48.57 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -12.37 million | -16.67 million |
| Change to Operating Activities | -17.44 million | 14.99 million | -10.71 million | 17.2 million | 33.44 million |
| Change in Cash | N/A | 65.91 million | N/A | 6.38 million | -13.48 million |
| Total Cash from Operating Activities | 78.49 million | 135.44 million | 66.07 million | 81.14 million | 51.76 million |
| Depreciation | N/A | N/A | N/A | 18.2 million | 17.7 million |
| Other Cash Flow from Investing Activities | 28000 | -55.91 million | -14000 | 108000 | -68000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | -40.15 million | 91000 |
| Other Cash Flow from Financing Activities | -11.39 million | -13.62 million | -10.1 million | -12.37 million | -16.67 million |
| Change to Net Income | -4.98 million | 67.88 million | -21.61 million | 37.26 million | -21.84 million |
| Capital Expenditures | N/A | N/A | N/A | 11.4 million | 11.7 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 573.14 million | 592.12 million | 558.76 million |
| Total Stockholder Equity | N/A | N/A | 736.42 million | 746.99 million | 705.47 million |
| Other Current Liabilities | 315.63 million | 237.23 million | 260.83 million | 265.46 million | 10.71 million |
| Total Assets | N/A | N/A | 1.31 billion | 1.34 billion | 1.26 billion |
| Common Stock | 17.14 million | 17.14 million | 736.42 million | 746.99 million | 17.14 million |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | 693.99 million |
| Other Liabilities | 108.75 million | 123.57 million | 122.8 million | 119.31 million | 115.15 million |
| Other Assets | 34.15 million | 32.21 million | 24.69 million | 27.15 million | 32.67 million |
| Cash | N/A | N/A | 173.73 million | 112.66 million | 113.86 million |
| Total Current Liabilities | 428.02 million | 345.01 million | 373.06 million | 384.76 million | 357.82 million |
| Other Stockholder Equity | 677.21 million | 692.72 million | N/A | N/A | -7.64 million |
| Property, Plant & Equipment | 186.77 million | 207.54 million | 224.73 million | 242.49 million | 221.35 million |
| Total Current Assets | 577.17 million | 534.13 million | 593.9 million | 620.44 million | 581.8 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 207.53 million | 239.28 million | 270.18 million | 297.96 million | 277.06 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 9.11 million | 13.76 million | 8.2 million | 7.83 million | 4.62 million |
| Accounts Payable | 19.86 million | 11.13 million | 15.58 million | 21.46 million | 33.2 million |
RaySearch Laboratories AB (publ) (RSLBF) Chart:
RaySearch Laboratories AB (publ) (RSLBF) News:
Below you will find a list of latest news for RaySearch Laboratories AB (publ) (RSLBF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
RaySearch Laboratories AB (publ) (RSLBF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
RaySearch Laboratories AB (publ) (RSLBF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|